Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung - Determination and validation of optimal prognostic cut-offs.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
07 2022
Historique:
received: 07 12 2021
revised: 22 03 2022
accepted: 25 04 2022
pubmed: 15 5 2022
medline: 22 6 2022
entrez: 14 5 2022
Statut: ppublish

Résumé

Prognostic stratification of patients with squamous cell carcinomas of the lung (SCC-L) is challenging. Therefore, we investigated several histomorphological parameters (tumour cell budding (TCB), spread through air spaces (STAS), tumour-stroma-ratio, immune cell infiltration) which could potentially serve as prognostic parameters in SCC-L. We aimed to systematically determine optimal cut-off-values and assess the prognostic capability of these patterns. We furthermore assessed interobserver variability (IOV) for prognostically significant patterns TCB and STAS. The Cancer Genome Atlas (TCGA) study cohort consisted of 335 patients with SCC-L. Histomorphological parameters analysed comprised TCB, minimal cell nest size (MCNS), STAS, stroma content and immune cell infiltration. The most significant cut-off-values were determined and univariate and multivariate survival outcomes were estimated. The identified cut-off-points were validated in an independent SCC-L cohort (n = 346 patients). Two experienced pathologists probed IOV in the validation cohort. In the TCGA study cohort, TCB, STAS and immune cell infiltration were identified as significant prognostic parameters. TCB-high tumours, a high number of STAS foci, extensive STAS for distance of STAS in alveoli and a low immune cell infiltration remained as independent prognostic factors in multivariate Cox proportional hazard analyses for overall survival (OS). The significance of TCB, number of STAS foci and distance of STAS in alveoli for OS could be validated in the validation cohort. IOV reached a Kappa ≥ 0.89 for prognostic parameters. We determined optimal cut-offs and identified TCB and STAS (number of STAS foci, distance of STAS in alveoli) as independent and uncorrelated prognostic factors for patients with SCC-L. The significance was validated in a large independent cohort. IOV was almost perfect for prognostic parameters. We propose the application of TCB- and STAS-based grading in SCC-L as prognostic morphological classifiers.

Identifiants

pubmed: 35567921
pii: S0169-5002(22)00425-1
doi: 10.1016/j.lungcan.2022.04.012
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Fabian Stögbauer (F)

Institute of Pathology, School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Manuela Lautizi (M)

Institute of Pathology, School of Medicine, Technical University of Munich (TUM), Munich, Germany; Chair of Experimental Bioinformatics, TUM School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany.

Mark Kriegsmann (M)

Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Hauke Winter (H)

Department of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany; Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Thomas Muley (T)

Translational Lung Research Center (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Katharina Kriegsmann (K)

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

Moritz Jesinghaus (M)

Institute of Pathology, School of Medicine, Technical University of Munich (TUM), Munich, Germany; German Cancer Consortium (DKTK), Germany; Institute of Pathology, University Hospital Marburg, Marburg, Germany.

Jan Baumbach (J)

Chair of Computational Systems Biology, University of Hamburg, Hamburg, Germany.

Peter Schüffler (P)

Institute of Pathology, School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Wilko Weichert (W)

Institute of Pathology, School of Medicine, Technical University of Munich (TUM), Munich, Germany; German Cancer Consortium (DKTK), Germany.

Tim Kacprowski (T)

Division Data Science in Biomedicine, Peter L. Reichertz Institute for Medical Informatics, TU Braunschweig and Hannover Medical School, 38106 Brunswick, Germany; Braunschweig Integrated Centre of Systems Biology (BRICS), 38106 Brunswick, Germany.

Melanie Boxberg (M)

Institute of Pathology, School of Medicine, Technical University of Munich (TUM), Munich, Germany; German Cancer Consortium (DKTK), Germany; Pathologie München-Nord, Munich, Germany. Electronic address: Melanie.Boxberg@tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH